Entero Healthcare Q1FY27: consolidated PAT +72% YoY to ₹52 Cr, OPM hits 5% target

Entero Healthcare's consolidated (primary) Q1 FY27 revenue came in at ₹1,940.50 Cr, up 38.2% YoY (₹1,403.82 Cr) and 1.6% QoQ (₹1,909.93 Cr). Consolidated PAT rose 72.2% YoY to ₹52.05 Cr (from ₹30.23 Cr) and 15.3% QoQ (from ₹45.13 Cr), with basic EPS at ₹8.77 versus ₹6.39 a year ago and ₹6.44 last quarter. There were no exceptional items in any of the three quarterly columns compared, so this is a clean read-through — unlike FY26's full-year number, which carried a ₹8.18 Cr consolidated exceptional charge. Margins expanded on both lines: OPM (EBITDA margin, calculated as PBT + finance cost + depreciation − other income, over revenue) moved to ~5.00% from 3.57% YoY and 4.50% QoQ, while NPM improved to ~2.68% from 2.14% YoY. That OPM print lands Entero right at management's stated FY27 target of 5% EBITDA margin in the very first quarter of the year — a genuine on-plan signal on profitability. Revenue growth is a murkier read: the company's own note to the consolidated statement says the quarter is not comparable with the year-ago period because seven entities (Ramson Medical, Sai RK Pharma, Well Wisher Pharma, Anand Medilink, Ace Cardiopathy, Bioaide Technologies, Anand Chemiceutics) were folded in at different dates through FY26. The filing gives no organic/like-for-like split, so the 38.2% YoY headline cannot be cleanly checked against management's guided 23% YoY growth ex-acquisitions — it likely overstates organic momentum. No Q1FY27-specific brokerage or consensus estimates turned up in search; the only figures found were stale Q4FY26 numbers, so vs-street is unknown rather than assumed. No management press release accompanied this filing beyond the standard board-outcome letter, so there is no fresh management commentary to weigh against the print — that is expected on the August 10 earnings call. Standalone results, which are secondary, tell a starkly different story: standalone PAT fell to ₹3.46 Cr from ₹6.96 Cr YoY and ₹13.42 Cr QoQ, but this reflects the holding company's own other-income/dividend flows rather than the group's trading operations, and should not be read as a profitability warning. Post-quarter, wholly-owned subsidiary RSM Pharma incorporated a further step-down subsidiary, Qurovia Lifesciences (25 July 2026), continuing the acquisition-led expansion that underpins the topline. Going into Q2, the earnings call is the key marker for whether management quantifies organic growth separately from M&A contribution, and whether the 5% EBITDA margin and ≥50% EBITDA-to-operating-cash-flow conversion targets hold as more FY26 acquisitions anniversary and integrate.